FibroBiologics stockholders approve capital stock increase and share issuance to YA II PN

FibroBiologics, Inc.

Authorized capital stock increased via amendment to certificate of incorporation effective June 12, 2025.
Stockholders elected Matthew Link and Victoria Niklas, M.D. as Class II directors until 2028.
Ratified WithumSmith+Brown, PC as independent auditor for FY 2025; votes: 53,940,908 for, 73,899 against, 528,109 abstain.
Approved issuance of common stock to YA II PN, LTD., exceeding 7,013,635 shares under Standby Equity Purchase Agreement.
Proxies representing 54,542,916 votes (77.4% of eligible) were present at the annual meeting.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

FibroBiologics, Inc.: The company filed an amendment to its Amended and Restated Certificate of Incorporation, effective June 12, 2025, to increase its authorized capital stock (effective 2025-06-12).

Change: charter amendment
Effective: 2025-06-12

Exact text from the filing

On June 12, 2025, FibroBiologics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized capital stock (the “Amendment”), which became effective the same day.

View on SEC.gov

102 governance changes filed in the last 30 days. Browse all governance changes →

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-015065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.